Abstract
Accumulating evidences from animal studies have indicated that both endogenous and exogenous IL-27, an IL-12 family of cytokine, can increase antitumor T-cell activities and inhibit tumor growth. IL-27 can modulate Treg responses, and program effector T cells into a unique T-effector stem cell (TSEC) phenotype, which enhances T-cell survival in the tumor microenvironment. However, animal studies also suggest that IL-27 induces molecular pathways such as IL-10, PD-L1 and CD39, which may downregulate tumor-specific T-cell responses. In this review paper, we will discuss the Yin and Yang aspects of IL-27 in the induction of tumor-specific T-cell responses, and the potential impacts of these functions of IL-27 in the design of cancer immunotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 191-200 |
| Number of pages | 10 |
| Journal | Immunotherapy |
| Volume | 7 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2015 |
Keywords
- IL-12
- IL-27
- T-effector stem cells
- cancer immunotherapy
- regulatory T cells
Fingerprint
Dive into the research topics of 'The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver